Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(12):887; doi:10.1093/jnci/93.12.887
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 12, 887, June 20, 2001
© 2001 Oxford University Press

IN THIS ISSUE

Viral Therapy Against Experimental Human Gliomas

Malignant gliomas are brain tumors characterized by their aggressiveness and resistance to standard therapies; long-term survival after diagnosis with this tumor is rare. On the basis of specific signaling pathways that are commonly activated in gliomas, investigators have attempted to use reovirus, a tumor-killing virus that exploits these pathways, to treat gliomas in experimental systems. Wilcox et al. (p. 903) tested the activity of reovirus against a variety of human malignant glioma cell lines and human tumors grown in mice and found that the virus killed most of the cell lines . . . [Full Text of this Article]

EGF Receptor, Gene Therapy, and Radiosensitivity

Prognostic Markers for Lymph Node-Negative Breast Cancer

Bone Mass and Breast Cancer Risk in Older Women

Helicobacter pylori and Risk of Pancreatic Cancer

Physical Activity and Ovarian Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?